Kiniksa Pharmaceuticals International, plc
KNSA
$76.75
-$1.08-1.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 58.85% | 56.71% | 60.09% | 55.68% | 56.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.85% | 56.71% | 60.09% | 55.68% | 56.18% |
| Cost of Revenue | 54.14% | 55.78% | 62.36% | 88.65% | 95.97% |
| Gross Profit | 63.01% | 57.49% | 58.26% | 34.64% | 32.44% |
| SG&A Expenses | 30.21% | 23.74% | 16.82% | 9.63% | 16.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.10% | 32.97% | 28.04% | 36.43% | 43.23% |
| Operating Income | 2,140.22% | 689.90% | 269.28% | 245.43% | 116.27% |
| Income Before Tax | 701.09% | 1,779.35% | 345.82% | 390.74% | 179.14% |
| Income Tax Expenses | 254.67% | 209.48% | 324.13% | 265.93% | 221.58% |
| Earnings from Continuing Operations | 1,583.88% | 531.02% | 236.61% | 496.10% | 146.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,583.88% | 531.02% | 236.61% | 496.10% | 146.82% |
| EBIT | 2,140.22% | 689.90% | 269.28% | 245.43% | 116.27% |
| EBITDA | 1,607.23% | 766.95% | 279.36% | 262.46% | 123.47% |
| EPS Basic | 1,649.50% | 509.31% | 231.11% | 490.40% | 141.83% |
| Normalized Basic EPS | 685.57% | 1,694.57% | 336.91% | 378.49% | 174.55% |
| EPS Diluted | 2,543.94% | 460.18% | 222.40% | 421.42% | 123.71% |
| Normalized Diluted EPS | 756.29% | 1,440.46% | 322.45% | 355.15% | 163.39% |
| Average Basic Shares Outstanding | 5.05% | 4.50% | 3.88% | 3.31% | 2.81% |
| Average Diluted Shares Outstanding | 9.82% | 10.56% | 10.50% | 7.14% | 4.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |